Core Insights - Palatin Technologies, Inc. announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint with highly statistically significant results, demonstrating the effectiveness of combining melanocortin-4 receptor (MC4R) agonist bremelanotide with GLP-1/GIP tirzepatide [1][2][4] Group 1: Study Results - The co-administered group experienced a 4.4% reduction in weight compared to a 1.6% reduction in the placebo group (p<0.0001) [4][5] - 40% of patients in the co-administered group achieved a 5% reduction in body weight, compared to 27% for the tirzepatide alone group (p<0.05) [5] - The study indicated that low-dose bremelanotide effectively halted weight regain after the cessation of tirzepatide treatment [4][6] Group 2: Future Developments - Palatin is advancing the development of next-generation MC4R long-acting peptides and oral small molecules, with IND applications planned for Q4 2025 and clinical data expected in H1 2026 [4][8] - The company is focusing on treatments for general obesity, weight loss management, and hypothalamic obesity, addressing significant unmet medical needs in a multi-billion-dollar market [9] Group 3: Mechanism and Market Context - The MC4R pathway is crucial for appetite regulation, and genetic mutations affecting this pathway can lead to obesity, highlighting the therapeutic potential of MC4R agonists [10] - Current GLP-1 receptor agonists face challenges such as side effects and treatment discontinuation, creating a demand for alternative therapies like MC4R agonists [9]